Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: WES of murine syngeneic models

PROVIDER: PRJNA506146 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8209100_1.fastq.gz	Fastqsanger.gz
	SRR8209100_2.fastq.gz	Fastqsanger.gz
	SRR8209110_1.fastq.gz	Fastqsanger.gz
	SRR8209110_2.fastq.gz	Fastqsanger.gz
	SRR8209101_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 26

Similar Datasets

Mus musculus strain:B6 | breed:SYN60

Project description:Murine syngeneic tumor models

| PRJNA314697 | ENA

Project description:RNASeq of murine syngeneic models

| PRJNA505989 | ENA

MM in murine models: WES

Project description:MM in murine models: WES

| PRJEB18119 | ENA

Differential expression of murine syngeneic orthotopic glioblastoma tumour models

Project description:Differential expression of murine syngeneic orthotopic glioblastoma tumour models

| PRJNA888952 | ENA

Differential expression of murine syngeneic orthotopic glioblastoma tumour models

Project description:Bulk RNA sequencing analysis of murine syngeneic orthotopic GL261-luc2 and CT2A-luc glioblastoma tumour models

2023-11-01 | GSE215123 | GEO

Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery [aCGH]

Project description:Murine syngeneic tumor models are the cornerstone of novel immuno-oncology (IO)-based therapy development but the molecular and immunological features of these models are still not clearly defined. The translational relevance of differences between the models is not fully understood, impeding appropriate preclinical model selection for target validation, and ultimately hindering drug development. Within a panel of commonly-used murine syngeneic tumor models, we showed variable responsiveness to IO-therapies. We employed aCGH, whole-exome sequencing, exon microarray analysis and flow cytometry to extensively characterise these models and revealed striking differences that may underlie these contrasting response profiles. We identified strong differential gene expression in immune-related pathways and changes in immune cell-specific genes that suggested differences in tumor immune infiltrates between models. We further investigated this using flow cytometry, which showed differences in both the composition and magnitude of the tumor immune infiltrates, identifying models that harbor ‘inflamed’ and ‘non-inflamed’ tumor immune infiltrate phenotypes. Moreover, we found that immunosuppressive cell types predominated in syngeneic mouse tumor models that did not respond to immune-checkpoint blockade, whereas cytotoxic effector immune cells were enriched in responsive models. A cytotoxic cell-rich tumor immune infiltrate has been correlated with increased efficacy of IO-therapy in the clinic and these differences could underlie the varying response profiles to IO-therapy between the syngeneic models. This characterisation highlighted the importance of extensive profiling and will enable investigators to select appropriate models to interrogate the activity of IO-therapies as well as combinations with targeted therapies in vivo.

2016-12-07 | GSE85508 | GEO

Project description:Whole exome sequencing analysis of murine syngeneic orthotopic glioblastoma tumour models

| PRJNA1056465 | ENA

Exploring the effects of DPP inhibition on the tumor immune landscape using RNAseq

Project description:We examined the effects of an oral small molecule DPP inhibitor (BXCL701) on PDAC tumor growth and tumor immune landscape using mT3-2D and Pan02 subcutaneous syngeneic murine models in C57BL/6 mice

2024-04-22 | GSE173441 | GEO

Project description:Syngeneic Murine Models with Distinct Immune Microenvironments Represent Subsets of Human Intrahepatic Cholangiocarcinoma

| PRJNA1066342 | ENA

Project description:WES of pancreatic PDX Models

| PRJNA800191 | ENA